Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke

Inclusion Criteria: * Full functional independence prior to the present stroke (as evidenced by a pre-morbid modified Rankin Scale score of 0-2 * Clinical diagnosis of acute stroke with CT scan ruling out intracranial hemorrhage * Onset of symptoms within 1-24 hours of commencement of infusion of study drug * Measurable deficit on NIHSS (as evidenced by a score of 3-15) * Full consciousness (i.e. the score for NIHSS item 1a=0) * Written valid informed consent is obtained from the subject or his/her next of kin or legal representative if the subject is fully conscious (i.e. the score for NIHSS item 1a = 0) but unable to read and/or sign the ICF, in accordance with National legislation and local IRB requirements Exclusion Criteria: * Subjects who are unlikely to complete the infusion of investigational product and/or are unlikely to undergo active medical management during that period due to a severe clinical condition * Subjects with severe illness with life expectancy less than 6 months * Body weight in excess of 120 kg * Subjects who have received rTPA or other thrombolytics (e.g. urokinase, streptokinase, reteplase, tenecteplase) within the previous 24 hours * Likelihood of forbidden concomitant therapy such as vascular surgery, coronary artery bypass graft (CABG), valve replacement, or carotid endarterectomy (CEA) * Evidence of cerebral herniation * Subjects with confounding neurological diseases such as dementia * Subjects with CADASIL, Moya Moya, or carotid dissection…